Skip to main content
Fig. 6 | Breast Cancer Research

Fig. 6

From: Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers

Fig. 6

NanoString immune-profiling analysis of tumor samples from control (C44), PS (mch1N11), and anti-PD-1 therapy. RNA isolated from tumors obtained at the study termination (shown in Fig. 3) was subjected to analysis utilizing the NanoString™ nCounter PanCancer Immune Profiling Panel. Expression values, expressed in log2 are graphically represented. a Profiling of tumor-associated immune cell type markers, including the markers for PD-1 and its ligand PD-L1. b Expression profiling of immune-activating-associated cytokines in each treatment group. c Expression profiling of immune-suppression-associated cytokines in each treatment group. DC dendritic cell, PD-1 programmed death 1, PD-L1 programmed death-1 ligand 1, Th T-helper, Treg regulatory T cell

Back to article page
\